These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33294255)

  • 1. Is AAV-delivered IL-27 a potential immunotherapeutic for cancer?
    Liu JQ; Zhu J; Hu A; Zhang A; Yang C; Yu J; Ghoshal K; Basu S; Bai XF
    Am J Cancer Res; 2020; 10(11):3565-3574. PubMed ID: 33294255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-Tumoral Delivery of IL-27 Using Adeno-Associated Virus Stimulates Anti-tumor Immunity and Enhances the Efficacy of Immunotherapy.
    Hu A; Ding M; Zhu J; Liu JQ; Pan X; Ghoshal K; Bai XF
    Front Cell Dev Biol; 2020; 8():210. PubMed ID: 32292786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy.
    Zhu J; Liu JQ; Shi M; Cheng X; Ding M; Zhang JC; Davis JP; Varikuti S; Satoskar AR; Lu L; Pan X; Zheng P; Liu Y; Bai XF
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Delivery of IL-12 Adjuvants Immunotherapy by Oncolytic Viruses.
    Vannini A; Leoni V; Campadelli-Fiume G
    Adv Exp Med Biol; 2021; 1290():67-80. PubMed ID: 33559855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of atherogenesis in LDLR knockout mice by systemic delivery of adeno-associated virus type 2-hIL-10.
    Liu Y; Li D; Chen J; Xie J; Bandyopadhyay S; Zhang D; Nemarkommula AR; Liu H; Mehta JL; Hermonat PL
    Atherosclerosis; 2006 Sep; 188(1):19-27. PubMed ID: 16300768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy.
    Nguyen HM; Guz-Montgomery K; Saha D
    Cells; 2020 Feb; 9(2):. PubMed ID: 32050597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene Therapy with an Adeno-Associated Viral Vector Expressing Human Interleukin-2 Alters Immune System Homeostasis in Humanized Mice.
    Durost PA; Aryee KE; Manzoor F; Tisch RM; Mueller C; Jurczyk A; Shultz LD; Brehm MA
    Hum Gene Ther; 2018 Mar; 29(3):352-365. PubMed ID: 28826231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors.
    Reul J; Frisch J; Engeland CE; Thalheimer FB; Hartmann J; Ungerechts G; Buchholz CJ
    Front Oncol; 2019; 9():52. PubMed ID: 30838171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells.
    Yong SB; Chung JY; Song Y; Kim J; Ra S; Kim YH
    Biomaterials; 2019 Oct; 219():119401. PubMed ID: 31398571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of an antitumoral immune response by wild-type adeno-associated virus type 2 in an in vivo model of pancreatic carcinoma.
    Eisold S; Schmidt J; Ryschich E; Gock M; Klar E; von Knebel Doeberitz M; Linnebacher M
    Pancreas; 2007 Jul; 35(1):63-72. PubMed ID: 17575547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.
    Wang Y; Huang F; Cai H; Wu Y; He G; Tan WS
    J Cancer Res Clin Oncol; 2010 Dec; 136(12):1827-37. PubMed ID: 20213096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic delivery of IL-27 by an adeno-associated viral vector inhibits T cell-mediated colitis and induces multiple inhibitory pathways in T cells.
    Zhu X; Liu Z; Liu JQ; Zhu J; Zhang J; Davis JP; Chu J; Yu J; Zhou J; Li MS; Bai XF
    J Leukoc Biol; 2016 Aug; 100(2):403-11. PubMed ID: 27106672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction and biological characterization of an interleukin-12 fusion protein (Flexi-12): delivery to acute myeloid leukemic blasts using adeno-associated virus.
    Anderson R; Macdonald I; Corbett T; Hacking G; Lowdell MW; Prentice HG
    Hum Gene Ther; 1997 Jun; 8(9):1125-35. PubMed ID: 9189770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesothelin-specific cell-based vaccine generates antigen-specific immunity and potent antitumor effects by combining with IL-12 immunomodulator.
    Chang MC; Chen YL; Chiang YC; Chen TC; Tang YC; Chen CA; Sun WZ; Cheng WF
    Gene Ther; 2016 Jan; 23(1):38-49. PubMed ID: 26262583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent antitumor effect of TRAIL mediated by a novel adeno-associated viral vector targeting to telomerase activity for human hepatocellular carcinoma.
    Wang Y; Huang F; Cai H; Zhong S; Liu X; Tan WS
    J Gene Med; 2008 May; 10(5):518-26. PubMed ID: 18338833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses.
    Ballesteros-Briones MC; Martisova E; Casales E; Silva-Pilipich N; Buñuales M; Galindo J; Mancheño U; Gorraiz M; Lasarte JJ; Kochan G; Escors D; Sanchez-Paulete AR; Melero I; Prieto J; Hernandez-Alcoceba R; Hervas-Stubbs S; Smerdou C
    Mol Ther; 2019 Nov; 27(11):1892-1905. PubMed ID: 31563534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.